ING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects

Clinical Infectious Diseases

Volumn 59, Issue 7, 2014, Pages 1032-1037

  Letendre, Scott L ^a   Mills, Anthony M ^b   Tashima, Karen T ^c   Thomas, Deborah A ^d   Min, Sherene S ^d   Chen, Shuguang ^d   Song, Ivy H ^d   Piscitelli, Stephen C ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b James R Berenson MD Inc   (United States)

^c MIRIAM HOSPITAL   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Cerebrospinal fluid; Dolutegravir; HIV

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DOLUTEGRAVIR; RALTEGRAVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR, LAMIVUDINE DRUG COMBINATION; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; LAMIVUDINE; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID-TO-PLASMA RATIO; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC50; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LUMBAR PUNCTURE; MALE; MULTICENTER STUDY; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; TREATMENT DURATION; UNBOUND FRACTION; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG COMBINATION; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PLASMA; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CEREBROSPINAL FLUID; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PLASMA; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84964314604     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu477     Document Type: Article

References (35)

1. Heaton RK, Clifford DB, Franklin DR Jr, et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 2087-96.
2. Heaton RK, Franklin DR, Ellis RJ, et al; CHARTER and HNRC Groups. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011; 17:3-16.
3. Spudich S, González-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med 2012; 2:a007120.
4. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010; 50:773-8.
5. Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010; 202:1819-25.
6. Letendre S, Capparelli E, Best B, et al. Better antiretroviral penetration into the central nervous system is associated with lower CSF viral load. In: 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, 5-8 February, 2006.
7. Letendre S, Marquie-Beck J, Capparelli E, et al; CHARTER Group. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
8. Cusini A, Vernazza PL, Yerly S, et al; the Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 2013; 62: 28-35.
9. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197(suppl 3):S294-306.
10. Gisslen M, Hagberg L, Rosengren L, et al. Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol 2007; 2:112-9.
11. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Ac-quir Immune Defic Syndr 2008; 47:544-52.
12. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders: I. Establishment of reference values. Scand J Clin Lab Invest 1977; 37:385-90.
13. Power C, Kong PA, Crawford TO, et al. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 1993; 34:339-50.
14. Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab 2006; 7:183-203.
15. Isaac A, Taylor S, Cane P, et al. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynam-ics in blood, CSF and semen. J Antimicrob Chemother 2004; 54: 498-502.
16. Yilmaz A, Izadkhashti A, Price RW, et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retroviruses 2009; 25:457-61.
17. 50 for wild-type HIV. J Antimicrob Chemother 2011; 66:354-57.
18. Yilmaz A, Gisslén M, Sudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4:e6877.
19. Raffi F, Jaeger H, Quiros-Roldan E, et al; extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antire-troviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2013; 13:927-35.
20. Walmsley SL, Antela AA, Clumeck N, et al; SINGLE Investigators. Do-lutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807-18.
21. Bennetto-Hood C, Tabolt G, Savina P, Acosta EA. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma. J Chromatog B Analyt Technol Biomed Life Sci 2014; 945-946:225-32.
22. Division of AIDS, National Institute of Allergy and Infectious Diseases. Division of AIDS table for grading the severity of adult and pediatric adverse events: version 1.0, December 2004; clarification August 2009. Available at: http://rsc.tech-res.com/Document/safetyandpharma covigilance/Table-for-Grading-Severity-of-Adult-Pediatric-Adverse- Events.pdf. Accessed 11 April 2014.
23. Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J 2011; 45:291-300.
24. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41:1787-93.
25. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Anti-microb Agents Chemother 2011; 55:813-21.
26. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA; HIV Neurobeha-vioral Research Center Group. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2000; 44:2173-5.
27. Croteau D, Letendre S, Best BM, et al; CHARTER Group. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother 2012; 56:1985-9.
28. Croteau D, Letendre S, Best BM, et al; CHARTER Group. Total ralte-gravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 2010; 54:5156-60.
29. Capparelli EV, Letendre SL, Ellis RJ, Patel P, Holland D, McCutchan JA. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2005; 49:2504-6.
30. Foudraine NA, Hoetelmans RMW, Lange JMA, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivu-dine plus zidovudine or stavudine. Lancet 1998; 351:1547-51.
31. Adam P, Sobek O, Táborský L, Hildebrand T, Tutterová O, Zácek P. CSF and serum orosomucoid (α-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients. Clin Chim Acta 2003; 334:107-10.
32. Haas DW, Johnson B, Nicotera J, et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 2003; 47:2131-7.
33. Croteau D, Rossi SS, Best BM, et al, CHARTER Group. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother 2013; 68:684-9.
34. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12: 111-8.
35. Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharma-cokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS 2011; 25:1737-45.